Clinical Trials on Infant,Premature in Canada

Total 530 results

Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
ProQR Therapeutics
European Commission

Completed

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

Cystic Fibrosis

United States, Spain, United Kingdom, Germany, Italy, Belgium, Canada, Czechia, Denmark, France
Mount Sinai Hospital, Canada
The Hospital for Sick Children; Sunnybrook Health Sciences Centre; University... and other collaborators

Recruiting

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

Late-Onset Neonatal Sepsis | Neonatal Hypotension | Extreme Prematurity

Canada, United States, Ireland, Israel
CF Therapeutics Development Network Coordinating...
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation

Completed

Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS)

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
Proteostasis Therapeutics, Inc.

Completed

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, France, Denmark, Germany
GlaxoSmithKline

Completed

28 Day Repeat Dose in Cystic Fibrosis Patients

Cystic Fibrosis

United States, France, Germany, Israel, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Spain, Germany, Italy, Austria, Belgium, Denmark
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
CF Therapeutics Development Network Coordinating...
Cystic Fibrosis Foundation

Completed

Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Inozyme Pharma

Active, not recruiting

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy | Autosomal Recessive Hypophosphatemic Rickets | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

United States, Canada, Germany, France, United Kingdom
Proteostasis Therapeutics, Inc.

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Cystic Fibrosis | Healthy Volunteer

United States, Canada, Denmark, Germany, Sweden
Shire

Terminated

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

Mucopolysaccharidosis (MPS)

United States, Canada, United Kingdom, Turkey, Italy, Mexico, Spain
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Foundation

Completed

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD)

Cystic Fibrosis

United States, Australia, Canada
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Study of Ataluren (PTC124™) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, United Kingdom, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Pharmaxis
ethica Clinical Research Inc.; Europe: KasaConsult bvba, Hoegaarden, Belgium; Argentina: Resolution Latin America; Buenos Aires, Argentina

Completed

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Canada, Argentina, Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Anthera Pharmaceuticals

Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
PTC Therapeutics

Terminated

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Cystic Fibrosis

United States, Spain, France, Belgium, United Kingdom, Australia, Brazil, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Argentina, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
AbbVie

Completed

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Cystic Fibrosis

United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
PTC Therapeutics
Cystic Fibrosis Foundation; ECFS-Clinical Trial Network (ECFS-CTN)

Completed

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Cystic Fibrosis

United States, Spain, United Kingdom, Netherlands, Germany, France, Belgium, Italy, Australia, Argentina, Brazil, Bulgaria, Canada, Greece, Israel, Poland
Gilead Sciences

Completed

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) (AIR-CF3)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Novartis

Terminated

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE)

Cystic Fibrosis

United States, Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico
Neovii Biotech

Completed

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Bronchiectasis | Idiopathic Pulmonary Fibrosis | Cystic Fibrosis | Chronic Obstructive Pulmonary | Pulmonary Vascular Disease

United States, Australia, Austria, Canada
Celtaxsys, Inc.

Completed

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Cystic Fibrosis

United States, United Kingdom, Canada, Belgium, France, Germany, Italy
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Cystic Fibrosis

United States, France, United Kingdom, Germany, Canada, Czech Republic, Ireland, Australia
Gilead Sciences

Completed

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa (AIR-CF1)

Cystic Fibrosis

United States, Canada, Australia, New Zealand
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Savara Inc.

Completed

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Cystic Fibrosis | MRSA

United States, Canada
Michael Morowitz
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

NICU Antibiotics and Outcomes Trial (NANO)

Microbial Colonization | Late-Onset Neonatal Sepsis | Necrotizing Enterocolitis of Newborn | Extreme Prematurity | Death; Neonatal | Early-Onset Neonatal Sepsis

United States, Canada
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Pulmonary Hypertension, Familial Persistent, of the Newborn

United States, Belgium, United Kingdom, Spain, Denmark, Germany, Sweden, Canada, France, Italy, Netherlands, Norway
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
Chris Goss
Medical University of South Carolina; University of Washington; Cystic Fibrosis... and other collaborators

Completed

Standardized Treatment of Pulmonary Exacerbations II (STOP2)

Pulmonary Cystic Fibrosis

United States, Canada
Pharmaxis

Completed

A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

Cystic Fibrosis

United States, Spain, Israel, Belgium, Czechia, South Africa, Italy, Mexico, Argentina, Australia, Canada, Hungary, New Zealand, Poland, Romania, Russian Federation, Slovakia, Ukraine
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom

Clinical Trials on Infant,Premature in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations